



- (51) **International Patent Classification:**
C07K 16/24 (2006.01) *A61K 39/00* (2006.01)
- (21) **International Application Number:**
PCT/IB2019/061461
- (22) **International Filing Date:**
31 December 2019 (31.12.2019)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/787,711 02 January 2019 (02.01.2019) US
62/838,190 24 April 2019 (24.04.2019) US
- (71) **Applicants:** **NEURACLE SCIENCE CO., LTD.** [KR/KR]; Sanhakgwan 702-2, Anam-ro 145, Seongbuk-gu, Seoul 02841 (KR). **SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION** [KR/KR]; 1, Gwanak-ro, Gwanak-gu, Seoul 08826 (KR).
- (72) **Inventors:** **KIM, Bongcheol**; 704-1602, 155, Dongpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13525 (KR). **KIM, Wonkyum**; Officetel Dong 825, Dongdaemun

Purugio-city, 104-3 Yongdu Dong, Dongdaemun-gu, Seoul 02578 (KR). **KIM, Dong Sik**; Doosan-Apt 114-1301 Bongcheon-ro 387, Gwanak-gu, Seoul 08750 (KR). **LEE, Jae-Keun**; 110-101 Lotte Castle Classic APT, 197, Seoun-ro, Seocho-gu, Seoul 06608 (KR). **YOON, Jeongwon**; 1217-402, 80, Dalbit-ro, Sejong-si 30064 (KR). **CHUNG, Junho**; Room 1801, T-dong, 170 Seohyun-ro, Bundang-gu, Seonhyun-dong, Poonglim eyeoneplus, Seongnam-si, Gyeonggi-do 13590 (KR). **JIN, Junyeong**; Room 1602, Floor 338, Byulyang-ro Woonmoon-dong, Raemian-sur Apartment, Gwachun-si, Gyeonggi-do 13835 (KR).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) **Title:** ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF




FIG. 13A

(57) **Abstract:** The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In some embodiments, antibodies are de-immunized to reduce immunogenicity in a human subject. In certain embodiments, antibodies have undergone affinity maturation. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g. inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*